Derivation and Characterization of a Dengue Type 1 Host Range-Restricted Mutant Virus That Is Attenuated and Highly Immunogenic in Monkeys

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Virology

• Publication date

  2002-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.76.7.3318-3328.2002PMID 11884557PMCID PMC136019
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Construction of a Full Length Infectious Clone for Dengue-1 Virus Western Pacific,74 Strain

  2004cited by this paper
• Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine

  2001cited by this paper
• A small region of the dengue virus-encoded RNA-dependent RNA polymerase, NS5, confers interaction with both the nuclear transport receptor importin-beta and the viral helicase, NS3.

  2001cited by this paper
• In Vitro RNA Synthesis from Exogenous Dengue Viral RNA Templates Requires Long Range Interactions between 5′- and 3′-Terminal Regions That Influence RNA Structure*

  2001cited by this paper
• Development of a fluorogenic RT-PCR system for quantitative identification of dengue virus serotypes 1-4 using conserved and serotype-specific 3' noncoding sequences.

  2001cited by this paper
• Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates

  2000cited by this paper
• Dengue: emergence as a global public health problem and prospects for control.

  2000cited by this paper
• Quantitative detection of dengue 2 virus using fluorogenic RT-PCR based on 3'-noncoding sequence.

  2000cited by this paper
• Identification and characterization of the RNA helicase activity of Japanese encephalitis virus NS3 protein

  2000cited by this paper
• Comments on the epidemiology, pathogenesis and control of dengue.

  1999cited by this paper
• Impact of dengue/dengue hemorrhagic fever on the developing world.

  1999cited by this paper
• The Serine Protease and RNA-Stimulated Nucleoside Triphosphatase and RNA Helicase Functional Domains of Dengue Virus Type 2 NS3 Converge within a Region of 20 Amino Acids

  1999cited by this paper
• Identification of Specific Nucleotide Sequences within the Conserved 3′-SL in the Dengue Type 2 Virus Genome Required for Replication

  1998cited by this paper
• Recombinant dengue virus type 1 NS3 protein exhibits specific viral RNA binding and NTPase activity regulated by the NS5 protein.

  1998cited by this paper
• trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication

  1997cited by this paper
• Translation elongation factor-1 alpha interacts with the 3' stem-loop region of West Nile virus genomic RNA

  1997cited by this paper
• Infectious RNA transcripts from full-length dengue virus type 2 cDNA clones made in yeast

  1997cited by this paper
• RNA-protein interactions: involvement of NS3, NS5, and 3' noncoding regions of Japanese encephalitis virus genomic RNA

  1997cited by this paper
• Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation

  1997cited by this paper
• Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys

  1996cited by this paper
• Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity.

  1996influential reference
• BHK cell proteins that bind to the 3' stem-loop structure of the West Nile virus genome RNA

  1995cited by this paper
• A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans.

  1994cited by this paper
• Targeted Recombination-Based Cloning and Manipulation of Large DNA Segments in Yeast

  1993cited by this paper
• Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus.

  1993cited by this paper
• HIV-1 Rev regulation involves recognition of non-Watson-Crick base pairs in viral RNA.

  1991cited by this paper
• Detection of stable secondary structure at the 3' terminus of dengue virus type 2 RNA.

  1991cited by this paper
• RNA recognition by Tat-derived peptides: interaction in the major groove?

  1991cited by this paper
• Flavivirus genome organization, expression, and replication.

  1990influential reference
• Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain).

  1989cited by this paper
• Dengue-4 vaccine: neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys.

  1988cited by this paper
• Sequence and secondary structure analysis of the 5'-terminal region of flavivirus genome RNA.

  1988cited by this paper
• Role of a bulged A residue in a specific RNA-protein interaction.

  1987cited by this paper
• Nucleotide sequence at the 3' end of Japanese encephalitis virus genomic RNA.

  1986cited by this paper
• Analysis of structural properties which possibly are characteristic for the 3'-terminal sequence of the genome RNA of flaviviruses.

  1986cited by this paper
• Partial sequence analysis of cloned dengue virus type 2 genome.

  1986cited by this paper
• Localization of the binding site for protein S4 on 16 S ribosomal RNA by chemical and enzymatic probing and primer extension.

  1986cited by this paper
• Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution.

  1985cited by this paper
• Stable secondary structures at the 3'‐end of the genome of yellow fever virus (17 D vaccine strain)

  1985cited by this paper
• Lack of viraemia and limited antibody response of dengue virus immune rhesus monkeys after vaccination with DEN-2/S-1 vaccine.

  1984cited by this paper
• Dengue-2 vaccine: viremia and immune responses in rhesus monkeys.

  1980cited by this paper
• Research on dengue during World War II.

  1952cited by this paper

• Generation and preliminary characterization of vertebrate-specific replication-defective Zika virus.

  2020influential citation
• Cis-acting Replication Element Variation of the Foot-and-mouth Disease Virus is Associated with the Determination of Host Susceptibility

  2020cites this paper
• RNA Structure Duplication in the Dengue Virus 3′ UTR: Redundancy or Host Specificity?

  2019cites this paper
• Animal Models for Dengue and Zika Vaccine Development.

  2018cites this paper
• Highly efficient production of a dengue pseudoinfectious virus.

  2014cites this paper
• Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis.

  2014cites this paper
• Utility, Limitations, and Future of Non-Human Primates for Dengue Research and Vaccine Development

  2014cites this paper
• Development of a live attenuated vaccine candidate against duck Tembusu viral disease.

  2014cites this paper
• A Chimeric Dengue Virus Vaccine using Japanese Encephalitis Virus Vaccine Strain SA14-14-2 as Backbone Is Immunogenic and Protective against Either Parental Virus in Mice and Nonhuman Primates

  2013cites this paper
• Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus.

  2013cites this paper
• Strategy to Diagnose Dengue Virus Infection in Local Settings: An Experience

  2013cites this paper
• Dengue Virus

  2010cites this paper
• The NS3 protein from dengue virus : structure and function

  2009cites this paper
• Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis.

  2009cites this paper
• Dengue: recent advances in biology and current status of translational research.

  2009cites this paper
• A unique approach to the synthesis of a dengue vaccine and the novel tetrasaccharide that results

  2009cites this paper
• Chapter 19 – Dengue

  2009cites this paper
• Viremia and antibody response in green monkeys (Chlorocebus aethiops sabaeus) infected with dengue virus type 2: A potential model for vaccine testing

  2009cites this paper
• Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.

  2008cites this paper
• Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates.

  2008cites this paper
• Dengue vaccines for travelers

  2008cites this paper
• The history and evolution of human dengue emergence.

  2008cites this paper
• Genetic analysis of Dengue 3 virus subtype III 5' and 3' non-coding regions.

  2008cites this paper
• Reverse genetics and the study of dengue virus

  2008cites this paper
• Aspects récents de la dengue dans les départements français d’Amérique

  2008cites this paper
• Attenuated West Nile viruses bearing 3'SL and envelope gene substitution mutations.

  2008cites this paper
• Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins

  2008cites this paper
• Vaccines against dengue: a review of current candidate vaccines at advanced development stages.

  2007cites this paper
• Potential of ancestral sylvatic dengue-2 viruses to re-emerge.

  2007cites this paper
• Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine.

  2007cites this paper
• The Live Attenuated Dengue Serotype 1 Vaccine rDEN1Δ30 is Safe and Highly Immunogenic in Healthy Adult Volunteers

  2006cites this paper
• Dengue virus RNA polymerase NS5: a potential therapeutic target?

  2006cites this paper
• A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates.

  2006cites this paper
• Recent advances in flavivirus antiviral drug discovery and vaccine development.

  2006cites this paper
• Development of novel vaccines for the concurrent immunisation against multiple dengue virus serotypes

  2006cites this paper
• Yellow fever vaccine

  2005cites this paper
• Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand.

  2005cites this paper
• Virus west nile presentant des mutations au niveau de la structure secondaire tige-boucle situee au niveau de l'extremite 3' destine a etre utilise en tant que vaccins a virus actifs

  2005cites this paper
• End-to-end communication in the modulation of translation by mammalian RNA viruses

  2005cites this paper
• Yellow fever vaccine

  2005cites this paper
• Size Heterogeneity in the 3′ Noncoding Region of South American Isolates of Yellow Fever Virus

  2005influential citation
• 5′- and 3′-noncoding regions in flavivirus RNA

  2004cites this paper
• Dengue vaccine: priorities and progress

  2004cites this paper
• Recent advancement in flavivirus vaccine development

  2004cites this paper
• Desarrollo de vacunas frente a las infecciones por dengue

  2004cites this paper
• Yellow Fever Virus Region of South American Isolates of Noncoding ′ Size Heterogeneity in the 3

  2004cites this paper
• Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity.

  2004cites this paper
• Dengue: defining protective versus pathologic immunity.

  2004cites this paper
• Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2

  2004cites this paper
• Editorial: The challenge of dengue vaccine development and introduction

  2004cites this paper
• Viral Vaccines for Dengue: The Present and the Future

  2003influential citation
• Vacunas contra el virus dengue: desarrollo histórico

  2003cites this paper
• Traditional and novel approaches to flavivirus vaccines.

  2003cites this paper
• Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2

  2003cites this paper
• A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3′ Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys

  2003cites this paper
• Molecular determinants of virulence: the structural and functional basis for flavivirus attenuation.

  2003cites this paper
• Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells.

  2003cites this paper
• Dengue epidemiology: virus epidemiology, ecology, and emergence.

  2003cites this paper
• Policymakers' views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries.

  2003cites this paper
• Vaccines for the prevention of neglected diseases--dengue fever.

  2003cites this paper
• A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4.

  2003cites this paper
• Temperature sensitive mutations in the genes encoding the NS1, NS2A, NS3, and NS5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice

  2003cites this paper
• Enteric infections; hepatitis B, emphasis on vaccine delivery Related review: New immunization initiatives and progress toward the global control of hepatitis B (pp 465±469)

  2002cites this paper
• Accelerating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City, VietNam.

  2002cites this paper
• The future of dengue vaccines.

  2002cites this paper
• Vaccines aplenty

  2002cites this paper